A Phase 2, Multi-Center, Randomized, Placebo Controlled, Single-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
Latest Information Update: 10 Jun 2022
At a glance
- Drugs Hepcidin (Primary)
- Indications Haemochromatosis
- Focus Therapeutic Use
- Sponsors La Jolla Pharmaceutical Company
- 03 Mar 2020 Status changed from active, no longer recruiting to completed.
- 29 Jan 2020 This trial has been completed in France, according to European Clinical Trials Database
- 25 Nov 2019 Top-line results published in La Jolla Pharmaceutical Media Release